Corona Remedies IPO: An Analysis
The initial public offering (IPO) for Corona Remedies, valued at ₹655.37 crore, is starting slowly. The offer, which opened on December 8, 2025, involves selling up to 6.2 million shares. Early signs suggest investor interest is concentrated in specific areas, and the market is reacting positively.
Key Points
- IPO valued at ₹655.37 crore, offering 6.2 million shares.
- Shares priced between ₹1,008 and ₹1,062 per share.
- Retail investors show higher interest than institutional buyers.
- Grey market trends indicate a 27.31% premium over the price.
- The IPO closes on December 10, 2025, with a debut on Dec 15.
- Brokerages recommend subscribing, citing strong financial fundamentals.
So far, only 30% of the shares have been booked, with retail investors leading the way. They’ve taken up 45% of their allotted share amount, while non-institutional investors have taken up 31%. Qualified Institutional Buyers (QIBs) have only placed bids for 1,344 shares, which is much lower than the 12,88,732 shares set aside for them.
Grey market trends are helping the IPO. Unlisted shares of Corona Remedies were trading at approximately ₹1,352 per share. This suggests a grey market premium (GMP) of ₹290, or 27.31% above the upper end of the price range. This positive sentiment is encouraging investors.
Brokerages are also optimistic. Arihant Capital and SBI Securities both recommend subscribing to the IPO. They highlight strong financial results, a lean balance sheet, and prices that align with similar companies.
The IPO will be open for subscription until Wednesday, December 10, 2025. The company’s stock will likely debut on the stock market on Monday, December 15, 2025. Bigshare Services is managing the registration process, and Kotak Mahindra Capital, IIFL, and JM Financial are assisting with the sale.
It’s important to note that the company itself won’t receive any money from this IPO. Instead, the money will go to the shareholders who are selling their shares, after covering expenses and taxes.
“The encouraging market reaction and positive broker recommendations signal a promising debut for Corona Remedies on the stock market.
